This is a StreetInsider.com Premium Only Page

IVERIC bio (ISEE) – Press Releases

Jul 11, 2023 07:00 PM Astellas Completes Acquisition of Iveric Bio

Jul 5, 2023 04:05 PM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023 04:52 PM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2023 04:05 PM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2023 07:00 PM Astellas Enters into Definitive Agreement to Acquire Iveric Bio

Apr 30, 2023 07:00 PM Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

Apr 23, 2023 05:15 PM Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting

Apr 4, 2023 04:05 PM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 2, 2023 04:15 PM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 1, 2023 06:32 AM Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results

Mar 1, 2023 06:30 AM Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials

Feb 28, 2023 08:00 AM Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference

Feb 22, 2023 08:00 AM Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023

Feb 16, 2023 04:01 PM Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Feb 2, 2023 04:01 PM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2023 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2023 07:30 AM Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

Dec 20, 2022 07:30 AM Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Dec 2, 2022 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 30, 2022 11:38 PM Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock

Nov 30, 2022 04:01 PM Iveric Bio Announces Proposed Offering of Common Stock

Nov 17, 2022 04:01 PM Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

Nov 4, 2022 04:30 PM Iveric Bio to Present at Upcoming Investor Conferences

Nov 3, 2022 06:30 PM Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

Nov 3, 2022 06:30 AM Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

Nov 2, 2022 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 27, 2022 08:00 AM Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022

Oct 4, 2022 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 27, 2022 08:00 AM Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

Sep 7, 2022 08:00 AM Iveric Bio to Present at Upcoming Investor Conferences

Sep 6, 2022 06:00 AM Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

Sep 2, 2022 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 10, 2022 08:00 AM Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Aug 3, 2022 08:00 AM Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022

Aug 2, 2022 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 26, 2022 06:32 AM Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results

Jul 26, 2022 06:30 AM Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank

Jul 21, 2022 04:18 PM Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022

Jul 16, 2022 11:15 AM Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting

Jul 6, 2022 02:00 AM DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

Jul 5, 2022 07:30 AM Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®

Jul 1, 2022 04:52 PM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2022 07:00 AM Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

Jun 2, 2022 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 17, 2022 08:00 AM Iveric Bio to Present at the UBS Global Healthcare Conference 2022

May 16, 2022 08:00 AM Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference

May 4, 2022 06:32 AM Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results

May 4, 2022 06:30 AM Iveric Bio Announces Presentation of Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

May 3, 2022 08:00 AM Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 27, 2022 08:00 AM Iveric Bio to Report First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 4, 2022